Skip to content

    Hepatitis Health Center

    Font Size
    A
    A
    A

    FDA Panel Urges Approval of Hepatitis C Drug

    Advisory Panel Recommends Approval of Boceprevir to Treat Chronic Hepatitis C
    By Jamila Bey
    WebMD Health News
    Reviewed by Laura J. Martin, MD

    April 27, 2011 -- In an18-0 vote, an FDA advisory panel recommended approval of the drug boceprevir to treat hepatitis C.

    Panel members called boceprevir, manufactured by Merck & Co., a weapon in the fight against chronic hepatitis C virus (HCV) genotype 1 infection. Chronic HCV genotype 1 infection is the most common form of hepatitis in the U.S. and also the most difficult to treat.

    If approved by the FDA, boceprevir will have the brand name Victrelis.

    Boceprevir is an antiviral medication called a protease inhibitor that has proven effective in adults with liver disease who have been untreated or who have failed previous therapy. Protease inhibitors are commonly used to treat HIV infection. In the treatment of hepatitis C infection, boceprevir inhibits an enzyme, thereby suppressing replication of the hepatitis C virus.

    Despite the committee’s affirmative vote, the advisors also had reservations about boceprevir’s widespread usage.

    The drug has proven to reduce the viral load to levels that are undetectable in more than a third of the HCV patients who use it. But the main contention concerned increased incidents and severity of anemia when the drug is used in addition with a pair of commonly used HCV drugs, pegylated interferon and ribavirin.

    Additionally, there was an increase in patients’ reported psychiatric symptoms and suicidal thoughts among participants in the drug’s trials.

    The problem, according to panel members, is that the studies show great promise, but the small sample size of 1,500 patients among two trials and the lack of diversity among the trial’s participants raise questions. The committee raised nearly 40 points they wished to have Merck’s researchers investigate.

    While praising the drug as the greatest advancement to date in any HCV regimen, Marc Ghany, MD, of the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health, summarized the feelings of his fellow advisory board members: "The data speak for themselves. The challenge is going be how to use this medication in the greater population."

    Questions for Drugmaker

    Boceprevir isn’t effective in every patient, and the advisory committee criticized Merck researchers for not having the answers to questions they felt should have been considered in advance of coming before them. Patient representative Lynda Marie Dee, JD, of Baltimore, pulled no punches in her displeasure. “There are no drug interaction studies. I’m shocked we don’t have studies on depression. It’s very disappointing that this hasn’t already been done.”

    Today on WebMD

    Hepatitus C virus
    Types, symptoms and treatments.
    liver illustration
    Myths and facts about this essential organ.
     
    woman eating apple
    What you need to know.
    doctor and patient
    What causes it?
     
    Hepatitis C Treatment
    Article
    Syringes and graph illustration
    Tool
     
    liver illustration
    Quiz
    passport, pills and vaccine
    Slideshow
     
    Scientist looking in microscope
    Slideshow
    Fatty Liver Disease
    Article
     
    Digestive Diseases Liver Transplantation
    Article
    Picture Of The Liver
    Image Collection